We live in a world where technology is playing an increasingly significant role in our daily lives. In the biopharmaceutical industry, using artificial intelligence (AI) as a tool can help improve efficiency, discover new cures and treatments and enhance clinical trials.
The American biopharmaceutical sector is built on a strong foundation of intellectual property protections and a flexible regulatory framework, both of which foster life-saving innovation in the United States.
Recently, trade group Pharmaceutical Research Manufacturers of America (PhRMA) submitted comments in response to the White House Office of Science and Technology Policy’s request for information on developing a national AI action plan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
PhRMA submits comments to White House on artificial intelligence
We live in a world where technology is playing an increasingly significant role in our daily lives. In the biopharmaceutical industry, using artificial intelligence (AI) as a tool can help improve efficiency, discover new cures and treatments and enhance clinical trials.
The American biopharmaceutical sector is built on a strong foundation of intellectual property protections and a flexible regulatory framework, both of which foster life-saving innovation in the United States.
Recently, trade group Pharmaceutical Research Manufacturers of America (PhRMA) submitted comments in response to the White House Office of Science and Technology Policy’s request for information on developing a national AI action plan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
More on this story...
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze